Ventavis Offers Relief for Pulmonary Arterial Hypertension


September 8, 2009

Actelion Pharmaceuticals U.S. Inc. offers a 20 microgram per milliliter (mcg/mL) formulation of Ventavis, for the treatment of New York Heart Association Class III and IV pulmonary arterial hypertension (PAH). The new formulation was released in September 2009.

This increased strength formulation delivers the same dose of Ventavis in half the volume, which is expected to reduce inhalation time and further support patient compliance. Ventavis is an inhaled synthetic analog of prostacyclin (PGI2) that produces potent pulmonary vasodilation and inhibits platelet aggregation, among other benefits. Prostacyclin functions as a hormone, binding to receptors on smooth muscle cells, thereby affecting their function. Prostacyclin has multiple physiological effects, including vasodilation, inhibition of platelet aggregation, antiproliferation, anti-inflammation, and enhanced cardiac contractility.

For more information: